Eungyosan

PreclinicalSmall molecule

KKorean Medicine Hospital of Pusan National University

Eungyosan is one of 7 small molecule programs targeting Common Cold. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common ColdActive, not recruiting

Common ColdPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Common Cold

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Approved

1 2

Aleve

Tylenol

Clarinex

Advil

Atrovent

Eungyosan

KKorean Medicine Hospital of Pusan National University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Common Cold1 trial

Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold

Unknown status·KKorean Medicine Hospital of Pusan National University·N/A·NCT04073511·375 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eungyosan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Eungyosan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Eungyosan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korean Medicine Hospital of Pusan National University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKorean Medicine Hospital of Pusan National University

Eungyosan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Common Cold1 trial

References

Drug Info

Quick Facts

Related News